DrugPatentWatch – Make Better Decisions's articles Biotechnology Which pharmaceutical drugs have the most drug patents in Austria? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in Austria are: Adasuve Abilify Maintena Kit Vistogard Zetia Abilify Nucynta […] Written by DrugPatentWatch – Make Better Decisions September 10, 2024September 10, 2024 Saving Bookmark this article Bookmarked Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions August 25, 2024August 25, 2024 Saving Bookmark this article Bookmarked Biotechnology New patent for Abbvie drug RINVOQ LQ Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for RINVOQ+LQ Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib […] Written by DrugPatentWatch – Make Better Decisions June 19, 2024June 19, 2024 Saving Bookmark this article Bookmarked Biotechnology New tentative approval for MSN drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions June 2, 2024June 2, 2024 Saving Bookmark this article Bookmarked Biotechnology New patent for Neurocrine drug ONGENTYS Copyright © DrugPatentWatch. Initially revealed at https://www.drugpatentwatch.com/weblog/ Annual Drug Patent Expirations for ONGENTYS Ongentys is a drug marketed by Neurocrine and is included in a single NDA. It’s out there from two suppliers. There are 9 patents defending this drug. ONGENTYS drug worth tendencies. This drug has 100 and 13 patent relations in thirty-one international […] Written by DrugPatentWatch – Make Better Decisions May 13, 2024May 13, 2024 Saving Bookmark this article Bookmarked Biotechnology New patent expiration for Merck Sharp drug DUTREBIS Copyright © DrugPatentWatch. Initially revealed at https://www.drugpatentwatch.com/weblog/ Annual Drug Patent Expirations for DUTREBIS Dutrebis is a drug marketed by Merck Sharp Dohme and is included in a single NDA. There are two patents defending this drug. The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. Extra particulars can be found on the lamivudine; raltegravir potassium […] Written by DrugPatentWatch – Make Better Decisions April 11, 2024April 11, 2024 Saving Bookmark this article Bookmarked Biotechnology New tentative approval for Sandoz Inc drug rifaximin Copyright © DrugPatentWatch. Initially printed at https://www.drugpatentwatch.com/weblog/ Rifaximin is the generic ingredient in a single branded drug marketed by Salix Pharms and is included in a single NDA. There are twenty-nine patents defending this compound. Drug patent litigation for RIFAXIMIN. This ingredient has 100 and eigthy-two patent members of the family in thirty-nine nations. Three […] Written by DrugPatentWatch – Make Better Decisions March 25, 2024March 25, 2024 Saving Bookmark this article Bookmarked Biotechnology New patent for Santen drug OMLONTI – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for OMLONTI Omlonti is a drug marketed by Santen and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. This drug has one hundred and fourteen patent family members in thirty-two countries. The generic ingredient […] Written by DrugPatentWatch – Make Better Decisions November 14, 2023November 14, 2023 Saving Bookmark this article Bookmarked Biotechnology New patent expiration for Ferrer Internacional drug XEPI – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for XEPI Xepi is a drug marketed by Ferrer Internacional and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. This drug has forty-four patent family members in twenty-five countries. The generic ingredient in XEPI […] Written by DrugPatentWatch – Make Better Decisions November 9, 2023November 9, 2023 Saving Bookmark this article Bookmarked Biotechnology New patent for Beigene drug BRUKINSA – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. This drug has forty-nine patent family members in twenty-eight countries. The generic ingredient in BRUKINSA is […] Written by DrugPatentWatch – Make Better Decisions November 4, 2023November 4, 2023 Saving Bookmark this article Bookmarked Biotechnology Drug Patent Expirations for the Week of October 22, 2023 – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ FINACEA (azelaic acid) Leo pharma as Patent: 8,900,554 Expiration: Oct 24, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com Make Better Decisions with DrugPatentWatch » Start Your Free Trial Today « Copyright © […] Written by DrugPatentWatch – Make Better Decisions October 25, 2023October 25, 2023 Saving Bookmark this article Bookmarked Biotechnology New patent expiration for Novartis drug VOTRIENT – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for VOTRIENT Votrient is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. This drug has thirty-four patent family members in twenty-five countries. The generic ingredient in VOTRIENT is […] Written by DrugPatentWatch – Make Better Decisions October 19, 2023October 19, 2023 Saving Bookmark this article Bookmarked Loading Load more
Biotechnology Which pharmaceutical drugs have the most drug patents in Austria? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in Austria are: Adasuve Abilify Maintena Kit Vistogard Zetia Abilify Nucynta […] Written by DrugPatentWatch – Make Better Decisions September 10, 2024September 10, 2024 Saving Bookmark this article Bookmarked
Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions August 25, 2024August 25, 2024 Saving Bookmark this article Bookmarked
Biotechnology New patent for Abbvie drug RINVOQ LQ Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for RINVOQ+LQ Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib […] Written by DrugPatentWatch – Make Better Decisions June 19, 2024June 19, 2024 Saving Bookmark this article Bookmarked
Biotechnology New tentative approval for MSN drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions June 2, 2024June 2, 2024 Saving Bookmark this article Bookmarked
Biotechnology New patent for Neurocrine drug ONGENTYS Copyright © DrugPatentWatch. Initially revealed at https://www.drugpatentwatch.com/weblog/ Annual Drug Patent Expirations for ONGENTYS Ongentys is a drug marketed by Neurocrine and is included in a single NDA. It’s out there from two suppliers. There are 9 patents defending this drug. ONGENTYS drug worth tendencies. This drug has 100 and 13 patent relations in thirty-one international […] Written by DrugPatentWatch – Make Better Decisions May 13, 2024May 13, 2024 Saving Bookmark this article Bookmarked
Biotechnology New patent expiration for Merck Sharp drug DUTREBIS Copyright © DrugPatentWatch. Initially revealed at https://www.drugpatentwatch.com/weblog/ Annual Drug Patent Expirations for DUTREBIS Dutrebis is a drug marketed by Merck Sharp Dohme and is included in a single NDA. There are two patents defending this drug. The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. Extra particulars can be found on the lamivudine; raltegravir potassium […] Written by DrugPatentWatch – Make Better Decisions April 11, 2024April 11, 2024 Saving Bookmark this article Bookmarked
Biotechnology New tentative approval for Sandoz Inc drug rifaximin Copyright © DrugPatentWatch. Initially printed at https://www.drugpatentwatch.com/weblog/ Rifaximin is the generic ingredient in a single branded drug marketed by Salix Pharms and is included in a single NDA. There are twenty-nine patents defending this compound. Drug patent litigation for RIFAXIMIN. This ingredient has 100 and eigthy-two patent members of the family in thirty-nine nations. Three […] Written by DrugPatentWatch – Make Better Decisions March 25, 2024March 25, 2024 Saving Bookmark this article Bookmarked
Biotechnology New patent for Santen drug OMLONTI – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for OMLONTI Omlonti is a drug marketed by Santen and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. This drug has one hundred and fourteen patent family members in thirty-two countries. The generic ingredient […] Written by DrugPatentWatch – Make Better Decisions November 14, 2023November 14, 2023 Saving Bookmark this article Bookmarked
Biotechnology New patent expiration for Ferrer Internacional drug XEPI – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for XEPI Xepi is a drug marketed by Ferrer Internacional and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. This drug has forty-four patent family members in twenty-five countries. The generic ingredient in XEPI […] Written by DrugPatentWatch – Make Better Decisions November 9, 2023November 9, 2023 Saving Bookmark this article Bookmarked
Biotechnology New patent for Beigene drug BRUKINSA – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. This drug has forty-nine patent family members in twenty-eight countries. The generic ingredient in BRUKINSA is […] Written by DrugPatentWatch – Make Better Decisions November 4, 2023November 4, 2023 Saving Bookmark this article Bookmarked
Biotechnology Drug Patent Expirations for the Week of October 22, 2023 – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ FINACEA (azelaic acid) Leo pharma as Patent: 8,900,554 Expiration: Oct 24, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com Make Better Decisions with DrugPatentWatch » Start Your Free Trial Today « Copyright © […] Written by DrugPatentWatch – Make Better Decisions October 25, 2023October 25, 2023 Saving Bookmark this article Bookmarked
Biotechnology New patent expiration for Novartis drug VOTRIENT – DrugPatentWatch Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for VOTRIENT Votrient is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. This drug has thirty-four patent family members in twenty-five countries. The generic ingredient in VOTRIENT is […] Written by DrugPatentWatch – Make Better Decisions October 19, 2023October 19, 2023 Saving Bookmark this article Bookmarked
